Products for Research Use Only

Physostigmine-d3

CAT: 0804-HY-N6608S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N6608S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Physostigmine-d3 is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning[1][2][3][4].
CAS Number
1217704-11-4
Product Name Alternative
Eserine-d3
UNSPSC
12352005
Target
Cholinesterase (ChE) ; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Neuronal Signaling; Others
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
C[C@]12C3=CC(OC(NC([2H])([2H])[2H])=O)=CC=C3N([C@@]1([H])N(CC2)C)C
Molecular Formula
C15H18D3N3O2
Molecular Weight
278.36
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Jonathan D Kenny, et al. Physostigmine and Methylphenidate Induce Distinct Arousal States During Isoflurane General Anesthesia in Rats. Anesth Analg. 2016 Nov;123 (5) :1210-1219.|[3]Haase U, et al. Pharmakotherapie--physostigmin post OP [Pharmacotherapy--physostigmine administered post-operatively]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007;42 (3) :188‐189.|[4]Dong H, et al, Bertchume A, Vallera D, Csernansky JG. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl) . 2005;181 (1) :145‐152.|[5]Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr. 2007;19 (2) :201‐205.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported